Syn-lethality: An integrative knowledge base of synthetic lethality towards discovery of selective anticancer therapies

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Li, Xue Juan ^a   Mishra, Shital K ^a   Wu, Min ^b   Zhang, Fan ^a   Zheng, Jie ^a,c  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b INSTITUTE FOR INFOCOMM RESEARCH   (Singapore)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPHASE PROMOTING COMPLEX SUBUNIT 1; ANAPHASE PROMOTING COMPLEX SUBUNIT 3; ANAPHASE PROMOTING COMPLEX SUBUNIT 4; ANAPHASE PROMOTING COMPLEX SUBUNIT 6; AURORA B KINASE; CYCLIN A2; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; MYC PROTEIN; PROTEIN P53; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL FATE; DNA DAMAGE; GENE FUNCTION; GENE MUTATION; HIGH THROUGHPUT SCREENING; KNOWLEDGE BASE; LETHALITY; ONCOGENE; ONCOGENE K RAS; SYNTHETIC LETHALITY; TUMOR GENE; COMPUTER INTERFACE; DRUG DEVELOPMENT; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETICS; HUMAN; LETHAL GENE; MOLECULAR GENETICS; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; DATABASES, GENETIC; DRUG DISCOVERY; GENE REGULATORY NETWORKS; GENES, LETHAL; HUMANS; KNOWLEDGE BASES; MOLECULAR SEQUENCE ANNOTATION; SIGNAL TRANSDUCTION; USER-COMPUTER INTERFACE;

EID: 84901268976     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/196034     Document Type: Article

References (16)

1. Boyle P., Levin B. E., World Cancer Report 2008 IARC Press
2. Kaelin W. G., Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Medicine 2009 1 10, article 99 2-s2.0-76449110054 10.1186/gm99
3. Kaelin W. G. Jr., The concept of synthetic lethality in the context of anticancer therapy. Nature Reviews Cancer 2005 5 9 689 698 2-s2.0-25444497278 10.1038/nrc1691 (Pubitemid 41486362)
4. Hartwell L. H., Szankasi P., Roberts C. J., Murray A. W., Friend S. H., Integrating genetic approaches into the discovery of anticancer drugs. Science 1997 278 5340 1064 1068 2-s2.0-0030667434 10.1126/science.278.5340.1064 (Pubitemid 27517876)
5. Heiskanen M. A., Aittokallio T., Mining high-throughput screens for cancer drug targetslessons from yeast chemical-genomic profiling and synthetic lethality. WIREs Data Mining Knowl Discovery 2012 2 3 263 272
6. Wu M., Li X. J., Zhang F., Li X. L., Kwoh C. K., Zheng J., Meta-Analysis of Genomic and Proteomic Features To Predict Synthetic Lethality of Yeast and Human Cancer 2013 ACM-BCB
7. Yuen K. W. Y., Warren C. D., Chen O., Kwok T., Hieter P., Spencer F. A., Systematic genome instability screens in yeast and their potential relevance to cancer. Proceedings of the National Academy of Sciences of the United States of America 2007 104 10 3925 3930 2-s2.0-34247200412 10.1073/pnas.0610642104 (Pubitemid 47181555)
8. Conde-Pueyo N., Munteanu A., Solé R. V., Rodríguez-Caso C., Human synthetic lethal inference as potential anti-cancer target gene detection. BMC Systems Biology 2009 3, article 116 2-s2.0-74549130411 10.1186/1752-0509-3-116
9. Chatr-Aryamontri A., Breitkreutz B. J., Heinicke S., Boucher L., Winter A., Stark C., Nixon J., Ramage L., Kolas N., 'Donnell L. O., Reguly T., Breitkreutz A., Sellam A., Chen D., Chang C., Rust J., Livstone M., Oughtred R., Dolinski K., Tyers M., The biogrid interaction database: 2013 update. Nucleic Acids Research 2013 41 816 823 10.1093/nar/gks1158
10. Luo J., Emanuele M. J., Li D., Creighton C. J., Schlabach M. R., Westbrook T. F., Wong K.-K., Elledge S. J., A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the ras oncogene. Cell 2009 137 5 835 848 2-s2.0-66149091940 10.1016/j.cell.2009.05.006
11. Morandell S., Yaffe M. B., Exploiting synthetic lethal interactions between dna damage signaling, checkpoint control, and p53 for targeted cancer therapy. Progress in Molecular Biology and Translational Science 2012 110 289 314 10.1016/B978-0-12-387665-2.00011-0
12. Wang Y., Engels I. H., Knee D. A., Nasoff M., Deveraux Q. L., Quon K. C., Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004 5 5 501 512 2-s2.0-2342495721 10.1016/S1535-6108(04) 00113-8 (Pubitemid 38610251)
13. Le Meur N., Gentleman R., Modeling synthetic lethality. Genome Biology 2008 9 9, article 135 2-s2.0-53849103270 10.1186/gb-2008-9-9-r135
14. Nowsheen S., Cooper T., Stanley J. A., Yang E. S., Synthetic lethal interactions between egfr and parp inhibition in human triple negative breast cancer cells. PLoS ONE 2012 7 10 e46614 10.1371/journal.pone.0046614
15. Barbie D. A., Tamayo P., Boehm J. S., Kim S. Y., Moody S. E., Dunn I. F., Schinzel A. C., Sandy P., Meylan E., Scholl C., Fröhling S., Chan E. M., Sos M. L., Michel K., Mermel C., Silver S. J., Weir B. A., Reiling J. H., Sheng Q., Gupta P. B., Wadlow R. C., Le H., Hoersch S., Wittner B. S., Ramaswamy S., Livingston D. M., Sabatini D. M., Meyerson M., Thomas R. K., Lander E. S., Mesirov J. P., Root D. E., Gilliland D. G., Jacks T., Hahn W. C., Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009 462 7269 108 112 2-s2.0-70449091786 10.1038/nature08460
16. Dong Y., Li A., Wang J., Weber J. D., Michel L. S., Synthetic lethality through combined notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. Cancer Research 2010 70 13 5465 5474 2-s2.0-77954351997 10.1158/0008-5472.CAN-10-0173